Mylan challenges nod to Ranbaxy's $600-mn drug

22 Mar 2011 Evaluate

Ranbaxy’s right to sell a generic version of Pfizer’s cholesterol-lowering drug, Lipitor, in the United States for six months has been challenged in a court. This is considered a $600-million (Rs 2,700 crore) opportunity for the company. US-based Mylan Laboratories has sued the US Food and Drug Administration (FDA) for giving this opportunity to Ranbaxy. The company wants that all generic players including Mylan be allowed to enter the market as soon as the patent protection on Lipitor ends in November.

Ranbaxy holds the right as it was the first to challenge a later date patent on the drug and apply for supply of a generic, low-cost version as soon as the basic patent expires. According to Mylan, Ranbaxy was not eligible for marketing exclusivity because of “false and unreliable data” from its manufacturing site in Paonta Sahib, India, where Lipitor’s copies would be produced. The facility was earlier under the FDA scanner for falsifying data.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×